🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Recruitingn/aAges 18 Years - 75 YearsAllTing YANG
NCT07188077 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Aged between 18 and 75 years. 2. The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection. 3. Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required. 4. Case group patients must have complete supporting imaging and pathology data. Exclusion Criteria: 1. Presence of other systemic malignancies. 2. Presence of severe infections or metabolic disorders. 3. Use of antimetabolites or chemotherapy drugs within one week prior to sample collection. 4. Pregnant or lactating women. 5. Concurrent severe internal medical conditions (e.g., end-stage renal disease, heart failure, liver failure). 6. Patients unable to complete study requirements due to psychiatric disorders or cognitive impairment.
💊

What it tests

  • Not listed
📍

Where

1 site
The First Affiliated Hospital of Fujian Medical University
Fuzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy